Overview

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

Status:
Completed

Trial end date:
2021-03-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.

Phase:

Phase 2

Details

Lead Sponsor:

Yale University

Collaborators:

Vanderbilt University
Vanderbilt University Medical Center

Treatments:

Cytarabine
Idarubicin
Nintedanib